Cibus, Inc.
NASDAQ:CBUSBiotechnology
+$0.04 today
- Market cap
- $104.71M
- Beta
- 1.65
- P/E (TTM)
- -8.6
- EPS (TTM)
- -$0.16
Volume 0.25M
Average 0.51M
CBUS Account Payables
Amounts the company owes suppliers for goods and services received.
Cibus, Inc.NASDAQ: CBUS
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 20.2% from a year ago
Account payables stood at $5.41M at the end of Q1 FY2026, down 20.2% from a year earlier and down 33.0% from the prior quarter. Over 3 fiscal years it compounded at +187.4% a year.
Context
- Account payables amounted to 1.7% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -20.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 8.07M USD
- Year-over-year change
- +35.3%
- 4-year CAGR
- +59.1%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.07M | +35.3% |
| FY2024 | 2024-12-31 | 5.96M | -2.7% |
| FY2023 | 2023-12-31 | 6.13M | +1702.1% |
| FY2022 | 2022-12-31 | 340K | -73.0% |
| FY2021 | 2021-12-31 | 1.26M | — |
Account Payables vs competitors
How CBUS compares with its peers on the latest reported figures
- CBUS's Mar 2026 account payables of $5.41M is the 4th highest of the 10 companies compared; the peer median is $1.63M.
- Its year-over-year change of -20.2% is the 6th highest of 10, against a peer median of -18.9%.
- Account payables amounts to 1.7% of total assets for CBUS, versus a peer median of 2.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.19M | +45.5% | +57.4% | 13.4% | |
| Mar 2026 | $10.51M | +90.9% | +33.3% | 5.5% | |
| Mar 2026 | $5.73M | +353.1% | -33.2% | 2.4% | |
CBUSCibus, Inc. | Mar 2026 | $5.41M | -20.2% | +187.4% | 1.7% |
| Mar 2026 | $4.61M | -40.1% | -22.1% | 9.9% | |
| Mar 2026 | $1.63M | -54.6% | +1.7% | 1.7% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $1.16M | -68.5% | +36.1% | 1.1% |
| Mar 2026 | $1.01M | -18.9% | -29.1% | 1.6% | |
| Mar 2026 | $863K | -38.3% | — | 0.8% | |
| Mar 2026 | $852.37K | +18.6% | +13.7% | 2.0% | |
| Peer median (excluding CBUS) | $1.63M | -18.9% | +7.7% | 2.0% | |
Competitors are the stored peer set for CBUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 13.82M | 3.43M | 32.7M | 14.43M | 9.92M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 530K | 1.04M | 703K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 499K | 705K | 1.99M | 1.47M | 1.44M |
| Total Current Assets | 15.18M | 4.13M | 35.22M | 16.95M | 12.07M |
| Property, Plant & Equipment (Net) | 21.73M | 18.13M | 37.46M | 44.69M | 27.86M |
| Goodwill | 0 | 0 | 434.9M | 253.47M | 232.52M |
| Intangible Assets | 0 | 158K | 35.41M | 33.58M | 31.68M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 282K | 0 | 1.42M | 1.39M | 926K |
| Total Non-current Assets | 22.01M | 18.29M | 509.19M | 333.12M | 292.98M |
| Total Assets | 37.19M | 22.42M | 544.41M | 350.07M | 305.05M |
| Account Payables | 1.26M | 340K | 6.13M | 5.96M | 8.07M |
| Short-term Debt | 0 | 0 | 833K | 436K | 3.17M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 107K | 1.21M | 932K | 536K |
| Other Current Liabilities | 2.71M | 403K | 5.29M | 5.87M | 5.09M |
| Total Current Liabilities | 4.85M | 1.66M | 21.32M | 19.88M | 16.86M |
| Long-term Debt | 0 | 0 | 536K | 226K | 235.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 702K | 79K | 167.12M | 200.91M | 1.56M |
| Total Non-current Liabilities | 18.21M | 13.53M | 184.79M | 232.36M | 266.36M |
| Total Liabilities | 23.06M | 15.19M | 206.12M | 252.24M | 283.22M |
| Common Stock | 4K | 5K | 8K | 9K | 79K |
| Retained Earnings | (196.09M) | (212.15M) | (479.78M) | (731.17M) | (858.25M) |
| Accumulated OCI | 0 | 0 | 8K | 15K | 39K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 44.82M | 5.67M | 0 |
| Total Equity | 14.13M | 7.23M | 338.29M | 97.83M | 21.83M |
| Total Debt | 17.88M | 13.91M | 24.62M | 36.29M | 267.96M |
| Net Debt | 4.05M | 10.48M | (8.08M) | 21.85M | 258.04M |
Cibus, Inc.
NASDAQ:CBUS
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.